Advertisement
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the developmentof novel, proprietary antibody-based products for cancer, inflammation andautoimmune diseases. Three product candidates are currently in clinicaltrials. MT103, also known as MEDI-538, is the first product candidate based onMicromet's novel BiTE(R) antibody product development platform and is beingevaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. The BiTE antibody product development platform is based ona unique, antibody-based class of drugs that leverages the cytotoxic potentialof T cells in the treatment of cancer. T cells are the most powerful 'killercells' of the human immune system. Micromet has established a collaborationwith MedImmune, Inc. for MT103/MEDI-538. The second clinical stage productcandidate is adecatumumab, also known as MT201, a recombinant human monoclonalantibody which targets EpCAM expressing tumors. Adecatumumab is beingdeveloped for the treatment of patients with breast cancer. A phase 2aclinical trial in this indication has been completed and a phase 1b trialevaluating the safety and tolerability of MT201 in combination with docetaxelis currently ongoing in patients with metastatic breast cancer. Our thirdclinical stage product candidate is D93, also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cellgrowth by binding cleaved collagen. This product candidate is in phase 1clinical trials and is being developed by TRACON Pharmaceuticals for thetreatment of patients with cancer and age-related macular degenerationpursuant to a license agreement under which Micromet has granted TRACON theworldwide rights to develop and commercialize D93/TRC093. In addition,Micromet has established a collaboration with Nycomed for the development andcommercialization of MT203, Micromet's human antibody neutralizing theactivity of granulocyte/macrophage colony stimulating factor (GM-CSF), whichhas potential applications in the treatment of inflammatory diseases, such asrheumatoid arthritis, as well as autoimmune diseases.
SOURCE Micromet, Inc.
